Wall Street Unites to Raise $4.2 Million for Melanoma Research
Over 1,100 leaders from the private equity sector, innovatively joined forces for a noble cause by attending the 15th annual Leveraged Finance Fights Melanoma (LFFM) benefit at a renowned venue. The event, held not for financial gain but for altruism, resulted in an incredible $4.2 million raised for the Melanoma Research Alliance (MRA), celebrated for being the largest non-profit organization dedicated to melanoma research globally.
The Purpose Behind LFFM
The LFFM is regarded as a vital gathering for the leveraged finance community, aimed at promoting essential research on melanoma, the deadliest form of skin cancer. This impactful initiative was established in 2011 by melanoma survivors Brendan Dillon of Veritas Capital and Jeff Rowbottom from General Atlantic. Since its inception, the event has successfully amassed over $32 million towards research initiatives that are pivotal not only for melanoma treatment but also for advancing cancer treatment in general.
The financial support generated from LFFM has catalyzed several groundbreaking advancements in areas such as immunotherapy, artificial intelligence-driven early detection methods, and targeted therapies for various challenging melanoma types, including rare and underfunded categories such as mucosal, acral, uveal, and pediatric melanomas.
Voices of Change
In the words of co-founder Jeff Rowbottom, "LFFM demonstrates the remarkable possibilities when financial power is aligned with the mission of finding a cure." He passionately pointed out the significant returns on investment, stating that innovations in melanoma treatment are being adapted for over 30 other cancer types, showcasing the vast ripple effect of this fundraising event.
Leadership and Sponsors
The honor of co-chairing the event was shared among a distinguished group of industry leaders, including Clare Bailhé (MidCap Financial), Brendan Dillon (Veritas Capital), and many others affiliated with top-tier firms. The evening also attracted several leading sponsors, including prominent investment firms such as HPS, Veritas Capital, Apollo, and Kirkland & Ellis, further emphasizing the collective effort in advancing melanoma research.
Marc Hurlbert, PhD and CEO of MRA conveyed, "The $4.2 million raised through LFFM is transformative. Despite our significant progress, numerous patients are still faced with melanoma without effective treatments. This essential funding accelerates scientific exploration, fostering hope for patients and their families around the world."
The Importance of Melanoma Awareness
Melanoma is a growing health concern, with predictions indicating that over 100,000 individuals will receive a melanoma diagnosis in a forthcoming year. Alarmingly, a person dies from melanoma every hour, underscoring the disease's lethality if not caught early. It’s one of the most prevalent cancers among adolescents and young adults, with certain professions, including military personnel and outdoor workers, facing heightened risks mainly due to UV exposure.
The significant contributions backed by MRA's funding have led to 17 FDA-approved treatments over just a decade, demonstrating the profound impact of research on practical solutions for melanoma treatment.
About Melanoma Research Alliance (MRA)
The Melanoma Research Alliance, founded by Debra and Leon Black in 2007, stands at the forefront of melanoma research funding. Dedicated to eradicating melanoma, MRA supports cutting-edge investigative science aimed at improving prevention, diagnosis, treatment, and survivorship of this formidable disease. The organization has played a pivotal role in each significant melanoma research breakthrough, achieving remarkable efficacy with every dollar donated, as overhead costs are fully covered by the supporting Black family.
Frequently Asked Questions
What is the purpose of the LFFM event?
The LFFM event aims to raise funds for melanoma research, supporting advancements in treatment and care.
How much money was raised during the latest event?
This year, the event raised a record-breaking $4.2 million for the Melanoma Research Alliance.
Who founded the Melanoma Research Alliance?
The Melanoma Research Alliance was founded in 2007 by Debra and Leon Black.
Why is melanoma a rising concern?
With increasing diagnoses and a high mortality rate, melanoma poses significant risks, especially to young adults and those exposed to UV light.
What kind of research is funded by the MRA?
MRA funds innovative research related to prevention, early detection, treatment, and survivorship focused on melanoma.
